Legal & General Group
RNA

Legal & General Group’s Atrium Therapeutics RNA Stock Holding History

Legal & General Group’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.6K Buy
+5,657
New +$79.5K ﹤0.01% 2631

Other funds holding RNA

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
OCAI
O'Connor Alternative Investments New York $1.17B AUM
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Legal & General Group's RNA Position: Q1 2026 in Review

Legal & General Group opened a new position in Atrium Therapeutics (RNA) in Q1 2026: 5,657 shares worth $75.6K. The stake represents ﹤0.01% of the portfolio and ranks #2631 among its holdings.

162 funds tracked by Wall St. Rank hold RNA as of Q1 2026.

  • Legal & General Group held 5,657 shares of Atrium Therapeutics worth $75.6K as of Q1 2026.
  • Atrium Therapeutics was a new Legal & General Group position in Q1 2026.
  • Atrium Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2631 holding.
  • 162 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.